Cover Image
市場調查報告書

日本腦炎:開發中產品分析

Japanese Encephalitis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 227543
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
日本腦炎:開發中產品分析 Japanese Encephalitis - Pipeline Review, H1 2017
出版日期: 2017年05月16日 內容資訊: 英文 42 Pages
簡介

日本腦炎是動物與人類的共通傳染病,是由會影響腦周圍薄膜組織的黃病毒所引起,並藉由蚊子傳播。症狀有發燒、頭痛、肌肉酸痛、下痢、中風、肌肉無力、以及麻痺等。治療是以止痛藥及抗痙攣劑等來緩和症狀為目標。

本報告提供日本腦炎的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等相關之系統性資訊。

目錄

簡介

調查範圍

日本腦炎概要

治療藥的開發

  • 開發中產品:概要
  • 開發中治療藥:各企業
  • 開發中治療藥:各大學/機關
  • 開發中的產品:各企業
  • 開發中的產品:各大學/機關

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Ennaid Therapeutics LLC
  • Fab'entech SA
  • Indian Immunologicals Ltd
  • Kineta Inc
  • Livzon Pharmaceutical Group Inc
  • Panacea Biotec Ltd
  • Theravectys SA
  • Vaxine Pty Ltd
  • Zydus Cadila Healthcare Ltd

藥物簡介

  • FDX-000
  • 日本腦炎疫苗(11種)
  • KIN-1400
  • 日本腦炎·病毒感染用NS5抑制劑
  • 日本腦炎用合成胜肽

暫停的計劃

開發中止的產品

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9255IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Japanese Encephalitis - Pipeline Review, H1 2017, provides an overview of the Japanese Encephalitis (Infectious Disease) pipeline landscape.

Japanese encephalitis is a viral disease that infects animals and humans. It is caused by a flavivirus that affects the membranes around the brain. It is transmitted by mosquitoes. Symptoms include fever, headache, muscle pain, diarrhea, seizures, muscle weakness and paralysis. Treatment targets relief of symptoms like pain relievers and anticonvulsants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Japanese Encephalitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Japanese Encephalitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Japanese Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Japanese Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 5 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Japanese Encephalitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Japanese Encephalitis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Japanese Encephalitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Japanese Encephalitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Japanese Encephalitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Japanese Encephalitis (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Japanese Encephalitis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Japanese Encephalitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Japanese Encephalitis - Overview
    • Japanese Encephalitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Japanese Encephalitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Japanese Encephalitis - Companies Involved in Therapeutics Development
    • Ennaid Therapeutics LLC
    • Fab'entech SA
    • Indian Immunologicals Ltd
    • Kineta Inc
    • Livzon Pharmaceutical Group Inc
    • Panacea Biotec Ltd
    • Theravectys SA
    • Vaxine Pty Ltd
    • Zydus Cadila Healthcare Ltd
  • Japanese Encephalitis - Drug Profiles
    • FDX-000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis [strains 1, 3 and 5] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KIN-1400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Japanese Encephalitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Japanese Encephalitis - Dormant Projects
  • Japanese Encephalitis - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Japanese Encephalitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Japanese Encephalitis - Pipeline by Ennaid Therapeutics LLC, H1 2017
  • Japanese Encephalitis - Pipeline by Fab'entech SA, H1 2017
  • Japanese Encephalitis - Pipeline by Indian Immunologicals Ltd, H1 2017
  • Japanese Encephalitis - Pipeline by Kineta Inc, H1 2017
  • Japanese Encephalitis - Pipeline by Livzon Pharmaceutical Group Inc, H1 2017
  • Japanese Encephalitis - Pipeline by Panacea Biotec Ltd, H1 2017
  • Japanese Encephalitis - Pipeline by Theravectys SA, H1 2017
  • Japanese Encephalitis - Pipeline by Vaxine Pty Ltd, H1 2017
  • Japanese Encephalitis - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
  • Japanese Encephalitis - Dormant Projects, H1 2017
  • Japanese Encephalitis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Japanese Encephalitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top